[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369914-105":59,"doc-detail-369914-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bladder-cancer-immunotherapy-parallel-advances-in-bcg-optimization-and-next-generation-vaccine-platforms-review","Bladder cancer immunotherapy - parallel advances in BCG optimization and next-generation vaccine platforms - review","","Bladder cancer remains a major global health challenge, with advanced-stage disease carrying persistently poor outcomes despite growing clinical progress in cancer immunotherapy. BCG intravesical immunotherapy is established as first-line therapy for non-muscle-invasive bladder cancer, yet systemic toxicity, treatment unresponsiveness, and rapid bladder clearance limit its effectiveness. This descriptive review synthesizes recent advances in BCG optimization and emerging vaccine approaches, including peptides, antigen-presenting cells, viral vectors, and nucleic/nucleic-acid-based platforms, aiming to enhance tumor-targeted immune activation. It highlights the potential of next-generation vaccines to reshape bladder cancer management while addressing implementation barriers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bladder-cancer-immunotherapy-parallel-advances-in-bcg-optimization-and-next-generation-vaccine-platforms-review/369914/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bladder-cancer-immunotherapy-parallel-advances-in-bcg-optimization-and-next-generation-vaccine-platforms-review/369914.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is BCG used for non-muscle-invasive bladder cancer, and what limitations does it have?","Question",{"text":112,"@type":113},"BCG intravesical immunotherapy serves as first-line treatment for non-muscle-invasive bladder cancer. Its limitations include systemic toxicity, BCG unresponsiveness, and rapid bladder clearance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the purpose of emerging next-generation cancer vaccines discussed in the review?",{"text":117,"@type":113},"The review focuses on vaccines designed to activate T cells and stimulate patient immune responses targeting tumor cells. It covers multiple platform types, including peptides, antigen-presenting cells, viruses, and nucleic acids.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PD-1/PD-L1 pathway inhibition fit into modern bladder cancer immunotherapy?",{"text":121,"@type":113},"By preventing T-cell inactivation, anti-PD-1/PD-L1 antibodies reverse tumor immune evasion mechanisms. The review cites pembrolizumab, nivolumab, and atezolizumab as examples with promising results.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369914,1790632477,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","TYPE Review  \nPUBLISHED 26 September 2025 DOI 10.3389/fimmu.2025.1648698  \nOPEN ACCESS  \nEDITED BY  \nMariam Mathew George,  \nCornell University, United States  \nREVIEWED BY  \nMara Marcela Barrio, Fundacio´n C´ancer, Argentina Song Jiang,  \nNorthwestern Medicine, United States  \n*CORRESPONDENCE  \nYuanshan Cui  \n [doctorcuiys@163.com](doctorcuiys@163.com)[ ](doctorcuiys@163.com)Yuan Gao  \n [gaoyuan9386@163.com](gaoyuan9386@163.com)[ ](gaoyuan9386@163.com)†These authors share ﬁrst authorship  \nRECEIVED 17 June 2025  \nACCEPTED 09 September 2025  \nPUBLISHED 26 September 2025  \nCITATION  \nLi F, Wang D, Gao Y and Cui Y (2025) Bladder cancer immunotherapy parallel advances in BCG optimization and next-generation vaccine platforms.  \nFront. Immunol. 16:1648698 .  \ndoi: 10.3389/fimmu.2025.1648698  \nCOPYRIGHT  \n© 2025 Li, Wang, Gao and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBladder cancer immunotherapy parallel advances in BCG optimization and nextgeneration vaccine platforms  \nFengshuo Li 1†, Dawei Wang 2†, Yuan Gao 2* and Yuanshan Cui 2,3*  \n1 Department of Urology, The Afﬁliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China, 2 Department of Urology, Weifang People’s Hospital, Weifang, China, 3 Department of Urology, Yantai Yuhuangding Hospital, Yantai, China  \nBladder cancer (BCa) remains a signiﬁcant global health challenge with rising incidence and suboptimal outcomes in advanced stages. Although immunotherapy for urological cancers is not a new treatment, recent clinical advances have conﬁrmed the value of immunotherapy as a urological cancer treatment. In the ﬁeld of cancer immunotherapy, increasing attention has been focused on the use of cancer vaccines that activate T cells to target growing tumors. Despite Bacillus Calmette-Gurin (BCG) intravesical immunotherapy serving as the ﬁrst-line treatment for non-muscle-invasive bladder cancer (NMIBC), its limitations, including systemic toxicity, BCG unresponsiveness, and rapid bladder clearance-necessitate novel therapeutic strategies. This descriptive review synthesizes recent advances in BCG optimization and emerging cancer vaccines for BCa, including peptides, antigen-presenting cells, viruses, or nucleic acids, that seeks to stimulate the patient’s immune response targeting tumor cells. Our study underscores the transformative potential of next-generation vaccines in redeﬁning BCa management while addressing critical barriers to implementation.  \nKEYWORDS  \nbladder cancer, Bacillus Calmette-Gue´ rin vaccine, peptide-based vaccine, DC-based vaccine, virus-based vaccine, RNA-based vaccine, DNA-based vaccine, immunotherapy  \n1 Introduction  \nRanking as the ninth most common malignancy globally, urothelial carcinoma (UC) represents the predominant urinary system’s cancer. It exhibits bifurcated anatomical presentations: upper tract UC and lower tract UC (1) . BCa is the most common UC, ranking as the fourth most prevalent cancer in men, with an annual global incidence of >430,000 cases (2, 3) . Among incident bladder cancer cases, the NMIBC accounts for three-quarters of presentations, whereas muscle-invasive and metastatic forms constitute the remaining cases (4) . Although UC is more prevalent in the United States and Western Europe, its prevalence may be associated with high levels of industrialization, high smoking  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nrates, and exposure to environmental carcinogens. In recent years, the incidence of UC in China has been increasing. Disease manifestation escalates progressively with advanc","cbCaiuLwDBRmsEhq","https://ap.wps.com/l/cbCaiuLwDBRmsEhq","pdf",996784,"English","# Introduction\n## Clinical context and standard treatment\n## Limitations of BCG and need for novel strategies\n## Emerging immunotherapy directions","[{\"question\":\"Why is BCG used for non-muscle-invasive bladder cancer, and what limitations does it have?\",\"answer\":\"BCG intravesical immunotherapy serves as first-line treatment for non-muscle-invasive bladder cancer. Its limitations include systemic toxicity, BCG unresponsiveness, and rapid bladder clearance.\"},{\"question\":\"What is the purpose of emerging next-generation cancer vaccines discussed in the review?\",\"answer\":\"The review focuses on vaccines designed to activate T cells and stimulate patient immune responses targeting tumor cells. It covers multiple platform types, including peptides, antigen-presenting cells, viruses, and nucleic acids.\"},{\"question\":\"How does PD-1/PD-L1 pathway inhibition fit into modern bladder cancer immunotherapy?\",\"answer\":\"By preventing T-cell inactivation, anti-PD-1/PD-L1 antibodies reverse tumor immune evasion mechanisms. The review cites pembrolizumab, nivolumab, and atezolizumab as examples with promising results.\"}]","Bladder cancer immunotherapy - parallel advances in BCG optimization and next-generation vaccine platforms - review | PDF",1790185195,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31615cb89447131907ab7a9b73f1cbf3.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42895760201b02326ef6298a5f0e8360.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa4d86bc58940509bae83136b01c9a89.webp",981,693,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b1d8a081be82b45a66ae242c872c163.webp",980,1385]